Patient Centric Approaches for Phase I Combination Trials Come on Stage.

Published in: Cancer discovery (2023)

A disruptive clinical trial design allowed Drilon and colleagues to demonstrate proof of concept of the potential of PF-07284892 to overcome resistance mechanisms to targeted therapies in the clinic. See related article by Drilon et al. (7).

Keyphrases

clinical trial
case report
primary care
phase ii
study protocol
human health
open label
risk assessment
phase iii